牛牛AI助理已提取核心訊息
On February 29, 2024, Jennison Associates LLC filed an amended Schedule 13G/A with the Securities and Exchange Commission, disclosing a 10.8% ownership stake in Arcutis Biotherapeutics, Inc., amounting to 12,128,533 shares. Jennison Associates, a Delaware-based investment adviser, reported this stake as a result of its advisory role to various investment companies and institutional clients. Prudential Financial, Inc., which owns Jennison Associates, may also be deemed to have influence over the voting and disposal of the shares held by Jennison's managed portfolios. The filing clarified that the shares were acquired in the ordinary course of business and not with the intent to change or influence the control of Arcutis Biotherapeutics. The statement also emphasized that no single client owns more than 5% of the class of securities, and the shares are not held for any purpose related to changing or influencing the control of the company.
On February 29, 2024, Jennison Associates LLC filed an amended Schedule 13G/A with the Securities and Exchange Commission, disclosing a 10.8% ownership stake in Arcutis Biotherapeutics, Inc., amounting to 12,128,533 shares. Jennison Associates, a Delaware-based investment adviser, reported this stake as a result of its advisory role to various investment companies and institutional clients. Prudential Financial, Inc., which owns Jennison Associates, may also be deemed to have influence over the voting and disposal of the shares held by Jennison's managed portfolios. The filing clarified that the shares were acquired in the ordinary course of business and not with the intent to change or influence the control of Arcutis Biotherapeutics. The statement also emphasized that no single client owns more than 5% of the class of securities, and the shares are not held for any purpose related to changing or influencing the control of the company.
2024年2月29日，Jennison Associates LLC向美國證券交易委員會提交了經修訂的附表13G/A，披露了Arcutis Biotherapeutics, Inc. 10.8％的所有權，總額爲12,128,533股。總部位於特拉華州的投資顧問Jennison Associates報告了這筆股份，這是其向多家投資公司和機構客戶提供諮詢服務的結果。擁有Jennison Associates的保誠金融公司也可能被視爲對詹尼森管理投資組合持有的股票的投票和處置具有影響力。該文件澄清說，這些股份是在正常業務過程中收購的，並不是爲了改變或影響Arcutis Biotherapeutics的控制權。該聲明還強調，沒有一個客戶擁有超過該類別證券的5％，並且持有這些股份的目的不是與改變或影響公司控制權有關的任何目的。
2024年2月29日，Jennison Associates LLC向美國證券交易委員會提交了經修訂的附表13G/A，披露了Arcutis Biotherapeutics, Inc. 10.8％的所有權，總額爲12,128,533股。總部位於特拉華州的投資顧問Jennison Associates報告了這筆股份，這是其向多家投資公司和機構客戶提供諮詢服務的結果。擁有Jennison Associates的保誠金融公司也可能被視爲對詹尼森管理投資組合持有的股票的投票和處置具有影響力。該文件澄清說，這些股份是在正常業務過程中收購的，並不是爲了改變或影響Arcutis Biotherapeutics的控制權。該聲明還強調，沒有一個客戶擁有超過該類別證券的5％，並且持有這些股份的目的不是與改變或影響公司控制權有關的任何目的。
有用
沒用